Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0026493 | 0 | 0.5 | |
Echinococcus multilocularis | G protein coupled receptor 139 | 0.0214677 | 0.218956 | 0.225466 |
Onchocerca volvulus | 0.0026493 | 0 | 0.5 | |
Entamoeba histolytica | acyl-coA synthetase, putative | 0.0026493 | 0 | 0.5 |
Toxoplasma gondii | Acetyl-coenzyme A synthetase 2, putative | 0.0026493 | 0 | 0.5 |
Trypanosoma cruzi | fatty acid transporter protein-like, putative | 0.0861141 | 0.97113 | 1 |
Echinococcus granulosus | neuropeptide receptor | 0.0214677 | 0.218956 | 0.225466 |
Toxoplasma gondii | AMP-binding enzyme domain-containing protein | 0.0026493 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD6 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.085946 | 0.969175 | 1 |
Plasmodium vivax | acetyl-CoA synthetase, putative | 0.0026493 | 0 | 0.5 |
Onchocerca volvulus | 0.0026493 | 0 | 0.5 | |
Plasmodium falciparum | acetyl-CoA synthetase, putative | 0.0026493 | 0 | 0.5 |
Entamoeba histolytica | long-chain-fatty-acid--CoA ligase, putative | 0.0026493 | 0 | 0.5 |
Entamoeba histolytica | acyl-CoA synthetase, putative | 0.0026493 | 0 | 0.5 |
Loa Loa (eye worm) | AMP-binding enzyme family protein | 0.0885953 | 1 | 1 |
Brugia malayi | AMP-binding enzyme family protein | 0.0885953 | 1 | 1 |
Trypanosoma brucei | acetyl-CoA synthetase, putative | 0.0026493 | 0 | 0.5 |
Trichomonas vaginalis | antibiotic synthetase, putative | 0.0026493 | 0 | 0.5 |
Trichomonas vaginalis | antibiotic synthetase, putative | 0.0026493 | 0 | 0.5 |
Toxoplasma gondii | propionate-CoA ligase | 0.0026493 | 0 | 0.5 |
Echinococcus granulosus | long chain fatty acid transport protein 4 | 0.0861141 | 0.97113 | 1 |
Leishmania major | fatty acid transporter protein-like protein | 0.085946 | 0.969175 | 1 |
Trypanosoma brucei | long-chain-fatty-acid-CoA ligase, putative | 0.0026493 | 0 | 0.5 |
Onchocerca volvulus | 0.0026493 | 0 | 0.5 | |
Schistosoma mansoni | neuropeptide receptor | 0.0214677 | 0.218956 | 0.225466 |
Mycobacterium leprae | possible long-chain acyl-CoA synthase | 0.085946 | 0.969175 | 1 |
Echinococcus multilocularis | neuropeptide receptor | 0.0214677 | 0.218956 | 0.225466 |
Onchocerca volvulus | 0.0026493 | 0 | 0.5 | |
Entamoeba histolytica | acyl-CoA synthetase, putative | 0.0026493 | 0 | 0.5 |
Schistosoma mansoni | FFA transport protein | 0.0861141 | 0.97113 | 1 |
Mycobacterium ulcerans | long-chain-acyl-CoA synthetase | 0.0885953 | 1 | 1 |
Echinococcus multilocularis | long chain fatty acid transport protein 4 | 0.0861141 | 0.97113 | 1 |
Trypanosoma cruzi | fatty acid transporter protein-like, putative | 0.0861141 | 0.97113 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 0.7 mg kg-1 | Antimalarial activity as reduced parasitaemia against Plasmodium yoelii YM in CD1 mice (Mus musculus) after 7 peroral doses over 4 days | ChEMBL. | 18396855 |
IC50 (functional) | = 0.4 uM | Antimalarial activity against Plasmodium falciparum T9-96 infected Rhesus positive human erythrocytes by [3H]hypoxanthine uptake | ChEMBL. | 18396855 |
Inhibition (functional) | = -0.9 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 0 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 0.3 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 1.13 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 96 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 96 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 0.76 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = -9 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = -6 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 96 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 96 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.67 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.21494 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18396855 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.